TaiMed Biologics (TWO:4147) — Market Cap & Net Worth
Market Cap & Net Worth: TaiMed Biologics (4147)
TaiMed Biologics (TWO:4147) has a market capitalization of $425.63 Million (NT$13.51 Billion) as of May 3, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #13376 globally and #502 in its home market, demonstrating a -2.47% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying TaiMed Biologics's stock price NT$49.45 by its total outstanding shares 273202000 (273.20 Million). Analyse 4147 operating cash flow to see how efficiently the company converts income to cash.
TaiMed Biologics Market Cap History: 2015 to 2026
TaiMed Biologics's market capitalization history from 2015 to 2026. Data shows change from $2.22 Billion to $425.63 Million (-9.49% CAGR).
TaiMed Biologics Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how TaiMed Biologics's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.21x
TaiMed Biologics's market cap is 1.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.43 Billion | $2.08 Million | -$281.96 Million | 690.33x | N/A |
| 2017 | $1.59 Billion | $8.44 Million | -$524.55 Million | 188.76x | N/A |
| 2018 | $1.42 Billion | $241.04 Million | -$321.71 Million | 5.91x | N/A |
| 2019 | $852.99 Million | $704.50 Million | -$578.65 Million | 1.21x | N/A |
| 2020 | $723.88 Million | $722.49 Million | -$183.30 Million | 1.00x | N/A |
| 2021 | $607.68 Million | $413.44 Million | -$470.93 Million | 1.47x | N/A |
| 2022 | $608.54 Million | $563.01 Million | -$269.29 Million | 1.08x | N/A |
| 2023 | $705.80 Million | $491.78 Million | -$194.81 Million | 1.44x | N/A |
| 2024 | $740.23 Million | $610.16 Million | -$201.83 Million | 1.21x | N/A |
Competitor Companies of 4147 by Market Capitalization
Companies near TaiMed Biologics in the global market cap rankings as of May 3, 2026.
Key companies related to TaiMed Biologics by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
TaiMed Biologics Historical Marketcap From 2015 to 2026
Between 2015 and today, TaiMed Biologics's market cap moved from $2.22 Billion to $ 425.63 Million, with a yearly change of -9.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$425.63 Million | -19.20% |
| 2025 | NT$526.77 Million | -28.84% |
| 2024 | NT$740.23 Million | +4.88% |
| 2023 | NT$705.80 Million | +15.98% |
| 2022 | NT$608.54 Million | +0.14% |
| 2021 | NT$607.68 Million | -16.05% |
| 2020 | NT$723.88 Million | -15.14% |
| 2019 | NT$852.99 Million | -40.12% |
| 2018 | NT$1.42 Billion | -10.54% |
| 2017 | NT$1.59 Billion | +11.11% |
| 2016 | NT$1.43 Billion | -35.34% |
| 2015 | NT$2.22 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of TaiMed Biologics was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $425.63 Million USD |
| MoneyControl | $425.63 Million USD |
| MarketWatch | $425.63 Million USD |
| marketcap.company | $425.63 Million USD |
| Reuters | $425.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About TaiMed Biologics
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinica… Read more